Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)

Market Cap	3.43B +24.2%
Revenue (ttm)	632.13M -9.4%
Net Income	105.75M -26.6%
EPS	2.07
Shares Out	n/a
PE Ratio	32.45
Forward PE	26.59
Dividend	0.66 (0.90%)
Ex-Dividend Date	Jul 14, 2025

Volume	12,380
Average Volume	14,362
Open	77.40
Previous Close	76.85
Day's Range	76.50 - 78.10
52-Week Range	45.58 - 78.05
Beta	0.24
RSI	77.40
Earnings Date	Feb 25, 2026

About LON:0ILL

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1946
• Employees: 2,188
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2024, LON:0ILL's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial numbers in EUR